Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Weiss, Vivian L ^a,b   Lee, Timothy H ^a,b   Song, Hong ^a,b   Kouo, Theodore S ^a,b   Black, Chelsea M ^a,b   Sgouros, George ^a,b   Jaffee, Elizabeth M ^a,b   Armstrong, Todd D ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; CANCER VACCINE; ERBB2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER GROWTH; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; ANIMAL; CELL MOTION; EXPERIMENTAL NEOPLASM; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL MOVEMENT; IMMUNOLOGIC MEMORY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; RECEPTOR, ERBB-2; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 84863154124     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031962     Document Type: Article

References (73)

1. Curotto de Lafaille MA, Lafaille JJ, (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30: 626-635.
2. Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, et al. (2001) Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res 61: 5850-5856.
3. Mittendorf EA, Sharma P, (2010) Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines 9: 89-105.
4. Pardoll D, (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21: 807-839.
5. Singh NJ, Schwartz RH, (2006) Primer: mechanisms of immunologic tolerance. Nat Clin Pract Rheumatol 2: 44-52.
6. Sprent J, Webb SR, (1995) Intrathymic and extrathymic clonal deletion of T cells. Curr Opin Immunol 7: 196-205.
7. Huehn J, Siegmund K, Lehmann JC, Siewert C, Haubold U, et al. (2004) Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J Exp Med 199: 303-313.
8. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, et al. (2009) The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 10: 595-602.
9. Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, et al. (2003) Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 170: 4273-4280.
10. Guy CT, Cardiff RD, Muller WJ, (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961.
11. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, et al. (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201: 1591-1602.
12. Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, et al. (2008) Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest 118: 1700-1711.
13. Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, et al. (2007) A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 13: 3951-3959.
14. Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, et al. (2006) OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol 176: 974-983.
15. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, et al. (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69: 3077-3085.
16. Hogg N, Laschinger M, Giles K, McDowall A, (2003) T-cell integrins: more than just sticking points. J Cell Sci 116: 4695-4705.
17. Colantonio L, Iellem A, Clissi B, Pardi R, Rogge L, et al. (1999) Upregulation of integrin alpha6/beta1 and chemokine receptor CCR1 by interleukin-12 promotes the migration of human type 1 helper T cells. Blood 94: 2981-2989.
18. Haworth O, Hardie DL, Burman A, Rainger GE, Eksteen B, et al. (2008) A role for the integrin alpha6beta1 in the differential distribution of CD4 and CD8 T-cell subsets within the rheumatoid synovium. Rheumatology (Oxford) 47: 1329-1334.
19. Nguyen K, Sylvain NR, Bunnell SC, (2008) T cell costimulation via the integrin VLA-4 inhibits the actin-dependent centralization of signaling microclusters containing the adaptor SLP-76. Immunity 28: 810-821.
20. Sasaki K, Zhao X, Pardee AD, Ueda R, Fujita M, et al. (2008) Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. J Immunol 181: 104-108.
21. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ, (2002) Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 22: 146-167.
22. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, et al. (2009) IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 182: 6951-6958.
23. Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O, (2009) Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J Pathol 217: 21-31.
24. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
25. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, et al. (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213: 131-145.
26. Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, et al. (2009) Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res 69: 6256-6264.
27. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, et al. (2009) Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 137: 1270-1279.
28. Whiteside TL, (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912.
29. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90: 3539-3543.
30. Gilboa E, (2004) The promise of cancer vaccines. Nat Rev Cancer 4: 401-411.
31. Hege KM, Jooss K, Pardoll D, (2006) GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 25: 321-352.
32. McMahan RH, Slansky JE, (2007) Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol 17: 317-329.
33. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, et al. (2004) The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol 172: 6074-6079.
34. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, et al. (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198: 569-580.
35. Butler NS, Nolz JC, Harty JT, (2011) Immunologic considerations for generating memory CD8 T cells through vaccination. Cell Microbiol 13: 925-933.
36. Obar JJ, Lefrancois L, (2010) Memory CD8+ T cell differentiation. Ann N Y Acad Sci 1183: 251-266.
37. Marzo AL, Klonowski KD, Le Bon A, Borrow P, Tough DF, et al. (2005) Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol 6: 793-799.
38. Obar JJ, Khanna KM, Lefrancois L, (2008) Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 28: 859-869.
39. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, et al. (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4: 225-234.
40. Shi M, Ye Z, Umeshappa KS, Moyana T, Xiang J, (2007) Alpha tumor necrosis factor contributes to CD8(+) T cell survival in the transition phase. Biochem Biophys Res Commun 360: 702-707.
41. Chen DS, Soen Y, Stuge TB, Lee PP, Weber JS, et al. (2005) Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med 2: e265.
42. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP, (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6: 383-393.
43. June CH, (2007) Principles of adoptive T cell cancer therapy. J Clin Invest 117: 1204-1212.
44. Klebanoff CA, Gattinoni L, Restifo NP, (2006) CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211: 214-224.
45. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, et al. (1995) Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 3: 407-415.
46. Lyman MA, Nugent CT, Marquardt KL, Biggs JA, Pamer EG, et al. (2005) The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J Immunol 174: 2563-2572.
47. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, et al. (2005) CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174: 2591-2601.
48. Wong SB, Bos R, Sherman LA, (2008) Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 180: 3122-3131.
49. Janicki CN, Jenkinson SR, Williams NA, Morgan DJ, (2008) Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res 68: 2993-3000.
50. Lin YC, Chang LY, Huang CT, Peng HM, Dutta A, et al. (2009) Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity. J Immunol 182: 6095-6104.
51. Zelenay S, Lopes-Carvalho T, Caramalho I, Moraes-Fontes MF, Rebelo M, et al. (2005) Foxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci U S A 102: 4091-4096.
52. Ito T, Hanabuchi S, Wang YH, Park WR, Arima K, et al. (2008) Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 28: 870-880.
53. Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, et al. (2008) Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 180: 2967-2980.
54. Yi H, Zhen Y, Jiang L, Zheng J, Zhao Y, (2006) The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells. Cell Mol Immunol 3: 189-195.
55. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, et al. (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27: 5911-5918.
56. Kimpfler S, Sevko A, Ring S, Falk C, Osen W, et al. (2009) Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol 183: 6330-6337.
57. Radojcic V, Bezak KB, Skarica M, Pletneva MA, Yoshimura K, et al. (2010) Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother 59: 137-148.
58. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, et al. (2000) Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95: 2024-2030.
59. Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, et al. (2010) Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 115: 4384-4392.
60. Mattei F, Bracci L, Tough DF, Belardelli F, Schiavoni G, (2009) Type I IFN regulate DC turnover in vivo. Eur J Immunol 39: 1807-1818.
61. Baldridge MT, King KY, Goodell MA, (2011) Inflammatory signals regulate hematopoietic stem cells. Trends Immunol 32: 57-65.
62. Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, et al. (2011) Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 71: 661-665.
63. Correia-Neves M, Waltzinger C, Mathis D, Benoist C, (2001) The shaping of the T cell repertoire. Immunity 14: 21-32.
64. Kouskoff V, Signorelli K, Benoist C, Mathis D, (1995) Cassette vectors directing expression of T cell receptor genes in transgenic mice. J Immunol Methods 180: 273-280.
65. Khattri R, Cox T, Yasayko SA, Ramsdell F, (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4: 337-342.
66. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, et al. (2001) Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61: 3689-3697.
67. Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, et al. (2000) HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 60: 3569-3576.
68. Schulz M, Aichele P, Schneider R, Hansen TH, Zinkernagel RM, et al. (1991) Major histocompatibility complex binding and T cell recognition of a viral nonapeptide containing a minimal tetrapeptide. Eur J Immunol 21: 1181-1185.
69. Alaoui-Jamali MA, Paterson J, Al Moustafa AE, Yen L, (1997) The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem Cell Biol 75: 315-325.
70. Disis ML, Cheever MA, (1997) HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 71: 343-371.
71. Roederer M, Nozzi JL, Nason MC, (2011) SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79: 167-174.
72. Brechbiel MW, Pippin CG, McMurry TJ, Melenic D, Roselli M, et al. (1991) An effective chelating agent for labelling of monoclonal antibody with 212Bi for α-particle mediated radioimmunotherapy. J Chem Soc, Chem Commun 1991: 1169-1170.
73. Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, et al. (1995) A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol 22: 387-390.